Eli Lilly & Co. (LLY) Tops Q4 EPS by 18c; offers guidance

Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $2.49, $0.18 better than the analyst estimate of $2.31. Revenue for the quarter came in at $9.35 billion versus the consensus estimate of $8.95 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2024 EPS of $12.20-$12.70, versus the consensus of $12.38. Eli Lilly & Co. sees FY2024 revenue of $40.4-41.6 billion, versus the consensus of $39.138 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Workhorse Group (WKHS) Misses Q2 EPS by 77c
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18